Aim. To evaluate the prognostic value of circulating galectin-3 for cumulative survival in patients with chronic lymphocytic leukemia in remission. Materials and methods. One hundred fifty six out subjects with chronic lymphocytic leukemia in full or partial remission were enrolled in the study.Observation period was up to 12 months. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of galectin-3 was used. Hemodynamic evaluation was performed by transthoracic echocardiography. Results and discussion. Two hundred sixteen cumulative clinical events occurred in 51 patients (32,7%) within the follow-up, with their distribution being as follows: 7 deaths, 122 cardiac arrhythmias, 16 cardiac ischemic events, 3 strokes, 30 chronic heart failures and 38 hospital admissions for cardiovascular reasons. Medians of circulating levels of galectin-3 in free-events subject cohort and subjects cohort with cardiovascular events were 5,16ng/ml (95% confidence interval [CI] = 4,74-5,56 ng/ml) and 16,40 ng/ml (95% CI = 14,80-18,01 ng/ml) (p<0.001). In multivariate logistic regression circulating VE-catherin independently predicted cumulative cardiovascular events (odds ratio [OR] = 1,13; 95% CI = 1,07–1,25; p = 0.003) within 12 months of observation period. Conclusions. Among patients with chronic lymphocytic leukemia in remission increased circulating galectin-3 associates with increased cumulative cardiovascular events within 12 months.